Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. The advancement in microneedle technology may require navigating new regulatory pathways for approval, particularly for novel delivery systems that differ from established methods.